Suppressing Pancreatic Cancer Survival and Immune Escape via Nanoparticle-Modulated STING/STAT3 Axis Regulation

Area of Science:

• Oncology
• Immunotherapy
• Nanomedicine

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is lethal and resistant to immunotherapy.
• The stimulator of interferon gene (STING) pathway offers immunotherapy potential, but PDAC cells show limited response.
• Signal transducer and activator of transcription 3 (STAT3) is overexpressed in PDAC, promoting tumor survival and immune evasion.

Purpose of the Study:

• To investigate the therapeutic potential of targeting the STING/STAT3 signaling axis in PDAC.
• To develop a novel nanomedicine approach for codelivering STING agonists and STAT3 inhibitors.
• To evaluate the efficacy of this approach in enhancing anti-tumor immunity and improving PDAC treatment outcomes.

Main Methods:

• Design of tumor-penetrating liposomes for codelivery of STING agonist and STAT3 inhibitor.
• In vitro and in vivo evaluation of the nanoparticles' effect on the STING/STAT3 signaling axis.
• Assessment of tumor growth inhibition, immune cell activation (NK cells, CD8+ T cells), and overall immune response.

Main Results:

• Codelivery nanoparticles effectively regulated the STING/STAT3 axis, inhibiting tumor proliferation and survival.
• Treatment led to significant activation of NK cells and CD8+ T cells, boosting innate and adaptive immunity.
• The approach demonstrated potential for overcoming immunotherapy resistance in PDAC.

Conclusions:

• Regulating the STING/STAT3 axis via codelivery nanoparticles is a promising strategy for PDAC treatment.
• This approach enhances anti-tumor immunity and may improve clinical outcomes for PDAC patients.
• Further research into STING/STAT3 targeted therapies could revolutionize pancreatic cancer treatment.